

# Exploring the use of Bayesian statistical models to reduce the number of animals in control groups

Ros Walley, John Sherington, Joe Rastrick, Alex Vugler, Gill Watt

2016 NC3Rs/HESI workshop  
14<sup>th</sup>-15<sup>th</sup> September 2016



Christer, living with Parkinson's disease



Inspired by **patients.**  
Driven by **science.**

# Outline

## **Motivation**

- Using historical data via a Bayesian analysis to reduce animal numbers

## **Case study**

## **First steps**

## **Types of control groups**

## **Bayesian methodology**

## **Summary to date**

# Motivation

Using historic data  
– it's a part of life!

**“Forewarned is forearmed”**


**“The best qualification of a prophet is to have a good memory. ”**

**--Marquis of Halifax**

**.... Used in assessing hazards**



# Motivation



# Case study

## Background

**Mouse model to study inflammatory response after a challenge.**

**Measures a number of cytokines at 2.5 or 3hrs.**

**Includes test compounds + three control treatments:**

- Negative group (no challenge).
- 'Positive' group (challenge, no treatment).
- Comparator with known efficacy

**Main comparisons of interest:**

- Test compound vs. +ve group (untreated) – Does test compound reduce the response?

**Data on 19 studies available (reasonably consistent protocol).**

**Most frequent in-vivo assay in this therapeutic area.**

**Data typically presented an experiment at a time, in PRISM**



# First steps

## QC charts for control groups

Well received.

Introduces the idea of **expt-to-expt variation**.

Intuitively, the relevance of the historic controls depends on the size of the study to study variation.



Bayesian analysis can use the historic control information, down-weighting it according to the amount of experiment-to-experiment variation

# Types of control groups

- Not used for formal statistical comparisons. Example uses:
  - To ensure challenge is working; to establish a “window”; to check consistency with previous studies; to convert values to %.
  - Replace group with a range from a predictive distribution
- Used for formal comparison vs. test compounds/doses
  - Used as the comparison in t-tests ..etc
  - Combine down-weighted historic data with the current experiment

# Bayesian methodology


## Outline

- Analyse historic control treatment group data, excluding the last study.
  - Bayesian meta-analysis
- Analyse the last study
  - Show what would have happened if we had “bought into” the Bayesian approach; omit animals if necessary
- Possible options for future studies:
  - Omit all/some animals from all/some control groups.
  - Use historic data as prior information **combined with observed data** in a Bayesian analysis.
  - Use historic data to give a predictive distribution for control group. i.e. **don't include that treatment group in current study.**
- Statistical model based on meta-analytic predictive methodology in Neuenschwander et al



## Bayesian methodology (2)



“Replacing” control groups with predictive distributions



Suitable for control groups not used in statistical comparisons


# Case study

## Predictive distribution



# Bayesian methodology (4)



## Full Bayesian analysis



# Case Study

## Full Bayesian analysis

The Bayesian analysis gives narrower confidence intervals. It is comparable to using 3 extra animals (11 instead of 8)



# Summary to date

**Bayesian methods can reduce required resource (animal numbers)**

**To have the greatest impact, focus on studies repeated very frequently**

**QC charts provided an excellent introduction to between and within study variation**

## **Predictive approach developed for two models**

Biologists very positive; implementation underway

Potential saving: one control group per study

## **Full Bayesian approach developed for two models**

Modest savings in numbers of animals in case study presented here

More savings in the other pilot case – but assay is no longer run

Software issue; potentially lengthening turnaround times for rapid screens

Biologists suggested using a slightly less frequent assay as a pilot

# Reference

**Walley R, Sherington J, Rastrick J, Detrait E, Hanon E and Watt G Using Bayesian analysis in repeated preclinical in vivo studies for a more effective use of animals. Pharmaceutical Statistics 2016; 15(3):277-285, DOI: [10.1002/pst.1748](https://doi.org/10.1002/pst.1748)**

# Questions?

# Thanks!



# Bayesian meta-analytic predictive approach

Statistical model based on Neuenschwander et al (2010)

## ■ Historic data:, $h=1 \dots H$ :

Observed study data:  $Y_h \mid \theta_h, \sigma_a^2 \sim N(\theta_h, \sigma_a^2)$

Study means:  $\theta_1 \dots \theta_H \sim N(\mu, \tau^2)$

## ■ Predictions for next study, denoted by \*:

True study mean  $\theta^* \sim N(\mu, \tau^2) \Rightarrow$  prior for next study

Observed study mean  $\bar{Y}^* \mid \theta^*, \sigma_a^2 \sim N(\theta^*, \sigma_a^2/n^*) \Rightarrow$  predictive dn for next study

## ■ Priors and hyperpriors

$\mu$  has vague normal prior

$\tau$  has vague half normal prior (sensitivity analysis carried out)

$\sigma_a^2$  has vague gamma prior